Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
作者信息
Sabbagh Marwan Noel, Cummings Jeffrey
机构信息
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA.
Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, USA.
出版信息
Alzheimers Dement. 2021 Apr;17(4):702-703. doi: 10.1002/alz.12235. Epub 2020 Nov 1.
Abstract
摘要
相似文献
1
Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".对《未能证明阿杜卡单抗的疗效：对渤健公司2019年12月报告的EMERGE和ENGAGE试验的分析》的公开同行评论
Alzheimers Dement. 2021 Apr;17(4):702-703. doi: 10.1002/alz.12235. Epub 2020 Nov 1.
2
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.未能证明 aducanumab 的疗效：Biogen 报告的 EMERGE 和 ENGAGE 试验分析，2019 年 12 月。
Alzheimers Dement. 2021 Apr;17(4):696-701. doi: 10.1002/alz.12213. Epub 2020 Nov 1.
3
Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.阿杜卡努单抗治疗阿尔茨海默病：EMERGE、ENGAGE 和 PRIME 研究的汇总数据。
Sr Care Pharm. 2022 Aug 1;37(8):329-334. doi: 10.4140/TCP.n.2022.329.
4
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中，淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
5
Questions EMERGE as Biogen claims aducanumab turnaround.随着渤健公司宣布阿杜卡努单抗出现转机，问题随之而来。
Nat Rev Neurol. 2020 Feb;16(2):63-64. doi: 10.1038/s41582-019-0295-9.
6
Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.阿杜卡奴单抗在阿尔茨海默病治疗中的作用：挑战与机遇。
Clin Interv Aging. 2022 May 18;17:797-810. doi: 10.2147/CIA.S325026. eCollection 2022.
7
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.阿杜卡奴单抗3期研究中部分不一致结果的调查。
J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6.
8
Editorial: Aducanumab Trials EMERGE But Don't ENGAGE.社论：阿杜卡努单抗试验“出现”但未“引人关注” 。
J Prev Alzheimers Dis. 2022;9(2):193-196. doi: 10.14283/jpad.2022.37.
9
Making the Case for the Accelerated Withdrawal of Aducanumab.为加速撤市阿杜卡奴单抗辩护。
J Alzheimers Dis. 2022;87(3):999-1001. doi: 10.3233/JAD-220264.
10
Aducanumab: First Approval.阿杜卡奴单抗：首次获批
Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.
引用本文的文献
1
A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories.阿尔茨海默病假说的范围综述：单一和多种因素理论的综合。
J Alzheimers Dis. 2024;99(3):843-856. doi: 10.3233/JAD-230772.
2
A case for seeking sex-specific treatments in Alzheimer's disease.在阿尔茨海默病中寻求针对性别的治疗方法的理由。
Front Aging Neurosci. 2024 Feb 13;16:1346621. doi: 10.3389/fnagi.2024.1346621. eCollection 2024.
3
The supersaturation perspective on the amyloid hypothesis.淀粉样蛋白假说的过饱和观点。
Chem Sci. 2023 Oct 16;15(1):46-54. doi: 10.1039/d3sc03981a. eCollection 2023 Dec 20.
4
α-Casein-Loaded Proteo-liposomes as Potential Inhibitors in Amyloid Fibrillogenesis: Effects on a Model of Alzheimer's Disease.α-酪蛋白负载的蛋白脂囊泡作为淀粉样纤维生成的潜在抑制剂：对阿尔茨海默病模型的影响。
ACS Chem Neurosci. 2023 Nov 1;14(21):3894-3904. doi: 10.1021/acschemneuro.3c00239. Epub 2023 Oct 17.
5
Aducanumab in Alzheimer's Disease: A Critical Update.阿杜卡奴单抗治疗阿尔茨海默病：关键性更新。
Curr Med Chem. 2024;31(31):5004-5026. doi: 10.2174/0929867331666230727103553.
6
A protein aggregation platform that distinguishes oligomers from amyloid fibrils.一种能够区分低聚物和淀粉样纤维的蛋白质聚集平台。
Analyst. 2023 May 16;148(10):2283-2294. doi: 10.1039/d3an00487b.
7
Pharmacological effects of natural medicine ginsenosides against Alzheimer's disease.天然药物人参皂苷抗阿尔茨海默病的药理作用
Front Pharmacol. 2022 Nov 16;13:952332. doi: 10.3389/fphar.2022.952332. eCollection 2022.
8
A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice.一种新型的靶向C型凝集素受体的基于α-突触核蛋白的帕金森疫苗在小鼠中诱导出强效免疫反应和治疗效果。
Vaccines (Basel). 2022 Aug 30;10(9):1432. doi: 10.3390/vaccines10091432.
9
Effects of dose change on the success of clinical trials.剂量变化对临床试验成功率的影响。
Contemp Clin Trials Commun. 2022 Sep 5;30:100988. doi: 10.1016/j.conctc.2022.100988. eCollection 2022 Dec.
10
Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease.淀粉样肽和分泌酶在阿尔茨海默病的发病机制和治疗中的作用。
Biomolecules. 2022 Jul 17;12(7):996. doi: 10.3390/biom12070996.
本文引用的文献
1
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.未能证明 aducanumab 的疗效：Biogen 报告的 EMERGE 和 ENGAGE 试验分析，2019 年 12 月。
Alzheimers Dement. 2021 Apr;17(4):696-701. doi: 10.1002/alz.12213. Epub 2020 Nov 1.
2
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies.动力学指纹可区分抗 Aβ 抗体的作用机制。
Nat Struct Mol Biol. 2020 Dec;27(12):1125-1133. doi: 10.1038/s41594-020-0505-6. Epub 2020 Sep 28.
3
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.用于阿尔茨海默病所致轻度痴呆的 Solanezumab 试验。
N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971.
4
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.阿杜卡努单抗可减少阿尔茨海默病中的 Aβ 斑块。
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
5
Statins: past and present.他汀类药物：过去与现在。
Heart Views. 2011 Jul;12(3):121-7. doi: 10.4103/1995-705X.95070.
6
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.11C-PiB PET 评估 bapineuzumab 治疗阿尔茨海默病患者纤维状淀粉样β负荷的变化：一项 2 期、双盲、安慰剂对照、递增剂量研究。
Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
Zotero 插件